Why No Supplement Can Do What GLP-1 Medications Do (and Why Marketing Increasingly Implies Otherwise)

This site’s other weight-management base articles cover ingredients with real, if modest, evidence: chitosan, glucomannan, CLA, garcinia cambogia, green tea extract. All of them, in the best pooled analyses available, produce weight-loss effects measured in single-digit pounds. Prescription GLP-1 and dual-agonist medications, by contrast, have produced average body weight reductions in the range of 15% to 22% of starting body weight in large, rigorous randomized trials — an entirely different order of magnitude. This article exists because marketing language increasingly blurs that gap, borrowing the credibility and cultural momentum of GLP-1 medications’ genuinely impressive results to describe supplement ingredients whose own evidence looks nothing like it.

The short version

• FDA-approved GLP-1 and dual-agonist medications have trial evidence that is not comparable in scale to any dietary supplement ingredient reviewed on this site. Large phase 3 randomized trials found semaglutide (marketed as Wegovy) produced roughly 15% average body weight loss over 68 weeks, and tirzepatide (marketed as Zepbound) produced roughly 21-22% average body weight loss over a similar duration — with a head-to-head trial (SURMOUNT-5) finding tirzepatide outperformed semaglutide directly (20.2% versus 13.7% average weight loss).
• These medications work through a specific, well-characterized mechanism: they mimic the body’s own GLP-1 hormone (and, for tirzepatide, a second hormone, GIP), which slows gastric emptying and enhances satiety signaling to the brain — a mechanism confirmed through extensive pharmacological research, not a proposed or theoretical one.
• By contrast, this site’s berberine article (covering the same ingredient increasingly marketed online as “nature’s Ozempic”) found average weight reductions of roughly 2 to 4 kg (about 4.4 to 8.8 lb) in the available trials — modest, real, but not remotely comparable to the ~15-22% of total body weight seen in GLP-1 trials. Per a pharmacist-authored 2025 review, this “nature’s Ozempic” framing is “misleading and not supported by scientific evidence”: unlike GLP-1 medications, there’s little evidence berberine directly increases satiety, and any mechanistic parallels drawn (mostly to metformin, a different diabetes medication, not to GLP-1 receptor agonists specifically) remain clinically unproven.
• The FDA has been aggressive about one part of this landscape and, notably, almost silent on another — a real, worth-naming enforcement gap. The agency has sent large waves of warning letters (roughly 80 in September 2025, 30 more in February/March 2026, and 25 more in June 2026, one of these waves confirmed via the FDA’s own press release) to telehealth companies over illegal marketing of compounded semaglutide and tirzepatide — real drug ingredients sold outside the FDA-approved supply chain. But dietary supplements marketed with “natural GLP-1” or “nature’s Ozempic”-style language are a different regulatory category, and enforcement there has been strikingly thin: as of this research pass, the FDA has issued exactly one warning letter to a supplement company specifically over GLP-1-related claims (in December 2024) — a fact multiple supplement-industry regulatory attorneys have described as “surprising” and “astonishing” given how widespread this marketing language has become.
• Separately, “compounded” semaglutide and tirzepatide products (versions prepared by compounding pharmacies rather than the FDA-approved manufactured product) carry their own, different risk profile from supplement marketing. Per the FDA’s own June 2026 statement, the agency has found fraudulent compounded products with false labeling (including compounding pharmacies that don’t actually exist), unapproved salt forms of the active ingredients never evaluated for safety, and dosing errors — and, as of May 31, 2026, had logged 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. This is a distinct problem from supplement marketing (it involves real drug ingredients, not botanical extracts), but it’s part of the same broader landscape: products of varying legitimacy positioning themselves near a genuinely well-evidenced, high-demand drug category, in ways that make it harder for a buyer to tell what they’re actually getting.
• The practical takeaway: no dietary supplement ingredient with real trial evidence behind it, reviewed anywhere on this site, produces weight loss in the same range as FDA-approved GLP-1 or dual-agonist medications. A product or article using “natural GLP-1,” “nature’s Ozempic,” or similar language to describe a supplement ingredient is making an implicit comparison the underlying evidence does not support — and, depending on the specific wording, may cross into the kind of disease-treatment claim that dietary supplements are not permitted to make.

What the GLP-1 medication trial evidence actually shows

Semaglutide and tirzepatide are FDA-approved medications (for obesity/weight management under the brand names Wegovy and Zepbound, respectively, among other indications) that work by mimicking incretin hormones the body produces naturally after eating — GLP-1 for semaglutide, and both GLP-1 and GIP for tirzepatide, which is why tirzepatide is often described as a “dual agonist.” These hormones slow gastric emptying and signal satiety to the brain, which is a specific, pharmacologically confirmed mechanism, not a proposed or theoretical one the way many supplement-ingredient mechanisms are.

The trial evidence behind these effects is large-scale and consistent. Semaglutide’s STEP trial program found average weight reductions in the range of roughly 15% of body weight over 68 to 88 weeks. Tirzepatide’s SURMOUNT trial program found somewhat larger average reductions, in the range of roughly 20-22%. A direct head-to-head trial, SURMOUNT-5, compared the two medications in 751 adults with obesity or overweight and at least one weight-related health condition: tirzepatide produced an average 20.2% weight loss compared to semaglutide’s 13.7%, and nearly a third of tirzepatide patients (31.6%) achieved at least 25% body weight loss, compared to 16.1% of semaglutide patients. These are large, well-controlled, FDA-reviewed trials — an evidentiary standard no dietary supplement ingredient is required to meet before being sold.

Why “nature’s Ozempic” marketing is a category error, using berberine as the clearest example

Berberine is the most visible case of this exact marketing pattern, and this site’s own companion berberine article (part of the energy-focus and gut-health content) covers its actual evidence base in more depth. The short version, specific to the GLP-1 comparison: a 2025 pharmacist-authored review found available data suggest berberine produces modest weight reductions of approximately 2 to 4 kg (about 4.4 to 8.8 lb) — with results varying considerably and many trials showing little to no effect — “compared with the approximately 10% weight loss observed with incretin-based therapies.” The same review is direct about the mechanistic gap: “unlike GLP-1 receptor agonists, there is little evidence that berberine directly increases satiety,” and while some mechanistic parallels have been drawn to metformin (a different, older diabetes medication with its own distinct mechanism), “clinical equivalence is unproven.” A 2020 systematic review of 35 berberine studies reached a similar bottom line: promising for metabolic regulation broadly, but lacking “robust clinical data demonstrating meaningful weight loss outcomes.”

The pattern here is worth naming explicitly because it recurs across the “natural GLP-1” marketing space generally, not just for berberine: an ingredient with some real, modest, mechanistically distinct evidence gets rebranded using language borrowed from a much more thoroughly evidenced, much more effective prescription drug category, in a way that implies a comparability the two evidence bases don’t support. The same review notes berberine “has been referred to as ‘nature’s Ozempic’” on social media platforms, and calls that framing “misleading and not supported by scientific evidence” directly.

The FDA’s actual enforcement record: aggressive on compounded drugs, nearly silent on “natural GLP-1” supplements

This is the section that most needed correcting in this article’s research, and it’s worth explaining precisely, because the accurate picture is more interesting (and more useful to a reader) than the version this article’s first draft told.

The FDA has been genuinely aggressive about one specific problem: telehealth companies illegally marketing compounded semaglutide and tirzepatide — real GLP-1 drug ingredients, prepared outside the FDA-approved manufacturing and review process, sometimes fraudulently. Per the FDA’s own June 2026 public statement on this topic, the agency has identified fraudulent compounded products bearing false labeling, including cases where the compounding pharmacy named on the label doesn’t actually exist; products containing unapproved salt forms of the active ingredients (such as semaglutide sodium or semaglutide acetate) that differ from the FDA-approved active ingredient and have not been evaluated for safety or effectiveness; and dosing-error risks specific to compounded vial-based products, including cases where patients inadvertently administered doses far beyond the intended amount. As of May 31, 2026, the FDA had logged 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. Enforcement against this specific problem has come in visible waves: roughly 80 warning letters in September 2025, another 30 in a February/March 2026 round (confirmed via the FDA’s own press release announcing that specific action), and 25 more in June 2026.

Dietary supplements marketed using “natural GLP-1” or “nature’s Ozempic” language are a legally and practically different category from compounded drugs — and, despite how common this marketing has become, FDA enforcement specifically against it has been remarkably thin. As of this research pass, the agency has issued exactly one warning letter to a supplement company specifically over GLP-1-related claims: a December 2024 letter to a company marketing products under the names “Elily Veronvy” and “Elily Veronvy 40+,” which FDA determined were unapproved new drugs because they were “intended to prevent, treat or cure disease conditions and/or affect the structure or function of the body” — the products reportedly claimed to be better than Ozempic, FDA-approved, and clinically proven, paired with aggressive before-and-after marketing imagery. Regulatory attorneys who track this space have described the thinness of enforcement here as genuinely surprising given how widespread “nature’s Ozempic”-style claims have become across the supplement industry; one attorney’s assessment was that FDA “seems to be taking a fairly relaxed attitude” toward GLP-1 supplement claims specifically, as long as they’re framed as general structure/function claims (“supports GLP-1”) rather than direct drug-mimicking or disease claims, and that the clearest trigger for enforcement is combining a mechanism-mimicking claim (like “GLP-1 agonist”) with disease-adjacent language or overt drug comparisons.

For a reader, the practical upshot of this enforcement gap is not reassurance — it’s closer to the opposite. The fact that the FDA has taken little action against “natural GLP-1” supplement marketing doesn’t mean those claims have been reviewed and found acceptable; it means, per the regulatory attorneys covering this space, that enforcement resources have been concentrated elsewhere (specifically on the compounded-drug telehealth problem, which carries more acute physical risk) and that supplement marketers making structure/function-framed claims have so far mostly stayed just inside a compliance line that a stricter or better-resourced enforcement posture could tighten at any time. A claim not yet having drawn a warning letter is not the same as a claim being true.

What we could not check

• The STEP 1 trial’s specific figures (14.9% semaglutide vs. 2.4% placebo, 68 weeks, 1,961 participants) were cross-verified against multiple independent secondary sources (including a structured trial-summary reference and search-indexed coverage) and are consistent with the figure this article cites (~15%); the trial was published in the New England Journal of Medicine in 2021 and underpinned semaglutide’s approval as Wegovy. We did not read the primary NEJM publication directly. The SURMOUNT/SURMOUNT-5 tirzepatide figures (20-22% average, and the 20.2%-vs-13.7% head-to-head result) were not independently re-verified beyond the original search-summarized sources — this remains the weaker-verified numerical claim in this article and would benefit from a primary-source pull before publication.
• We read the Pharmacy Times berberine/GLP-1 comparison article in substantial detail via a saved fetch, though not confirmed as a peer-reviewed primary source — it is a professional pharmacy-trade publication piece authored by a PharmD candidate, itself citing (but not directly read by us) a 2020 systematic review of 35 berberine studies and a 2022 berberine review; this article’s berberine-specific figures should be considered once-removed from the primary trial data.
• The FDA’s own page on unapproved/compounded GLP-1 drugs was read in full and directly (2026-08-06 verification pass), confirming the compounded-drug adverse-event counts, the fraudulent-labeling and salt-form concerns, and the general shape of enforcement described in this article. The specific warning-letter counts (80/30/25) were cross-checked against multiple independent trade-press sources, and the February/March 2026 wave of 30 letters was confirmed against the FDA’s own press release (fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s) — a meaningfully stronger verification than this article’s first draft had. The claim that only one warning letter has been issued to a supplement company specifically for GLP-1-related claims is sourced to a single, but detailed and directly-read, industry trade publication (SupplySide Supplement Journal, May 2025), which itself quotes named regulatory attorneys and cites the specific FDA warning letter (Veronvy, December 2024) by name — this is a meaningfully strong secondary source (on-the-record attorney quotes, a specific named and dated FDA letter), but it was not cross-verified against a second independent source, and it’s possible additional supplement-specific warning letters have been issued since this article (May 2025) or this research pass (August 2026) that wouldn’t be reflected here.
• This article does not evaluate any specific commercial supplement product, compounded GLP-1 provider, or telehealth service, nor does it provide medical guidance on whether GLP-1 medications are appropriate for any individual reader — that determination belongs with a doctor.

Our rating, and why

Not applicable. This is a comparative-context and consumer-protection framework article, not a single-ingredient efficacy review — its purpose is to give readers a clear, numerically grounded sense of just how large the evidence and effect-size gap is between FDA-approved GLP-1 medications and any dietary supplement ingredient marketed alongside or in comparison to them, before any specific product’s “natural GLP-1” or “nature’s Ozempic”-style claim gets evaluated against it. This article deliberately does not evaluate GLP-1 medications themselves as a treatment option (that determination involves a doctor and an individual’s full medical picture) — it exists solely to correct the scale of comparison that a specific, active, FDA-flagged marketing pattern currently distorts.

Sources

1. Reese R. Is Berberine Nature’s GLP-1? Pharmacy Times. Published 2025-10-31. https://www.pharmacytimes.com/view/is-berberine-nature-s-glp-1- (read in substantial detail via saved fetch)
2. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (read in full directly, 2026-08-06 verification pass; content current as of 2026-06-15 per the page’s own timestamp)
3. U.S. Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. Press release. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s (referenced via search summary confirming the February/March 2026 warning-letter count; not read in full directly)
4. French R. Regulators mostly silent on GLP-1 supplement claims. SupplySide Supplement Journal. Published 2025-05-27. https://www.supplysidesj.com/supplement-regulations/regulators-mostly-silent-on-glp-1-supplement-claims (read in full directly, 2026-08-06 verification pass) — the source for the single-warning-letter (Veronvy, December 2024) finding, quoting named regulatory attorneys Asa Waldstein (Supplement Advisory Group), Marc Ullman (Rivkin Radler LLP), and Katie Bond (Keller and Heckman LLP)
5. Search-summarized secondary coverage of STEP (semaglutide) and SURMOUNT (tirzepatide) phase 3 trial results, including the SURMOUNT-5 head-to-head comparison; the STEP 1 figures specifically were cross-checked against a second independent summary source during the 2026-08-06 verification pass (not a primary publication read directly)

A note on this article’s revision history: an earlier draft of this article stated that “the FDA has specifically and repeatedly warned about this exact marketing pattern” (dietary supplements marketed as “natural GLP-1” alternatives), citing the same 80/30/25 warning-letter counts used in this revised version. Follow-up verification research (2026-08-06, prompted by Vinicius’s request to check this claim before publication) found this was materially misleading: those warning-letter waves target telehealth companies illegally marketing compounded drug GLP-1 products, a different regulatory problem from dietary-supplement “natural GLP-1” marketing claims. Direct FDA enforcement specifically against supplement companies for GLP-1-related claims has in fact been extremely limited — one warning letter, as of this research pass. The article body above has been rewritten to state this distinction accurately; the corrected version is, if anything, a more useful and more surprising finding for a reader than the original draft’s (inaccurate) claim of “specific and repeated” FDA warnings against supplement marketing specifically.